Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Schnell O
Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas
European Association of NeuroOncology Magazine 2014; 4 (3): 109-115

PDF    Summary    Overview   

Fig. 1: MGMT This Image - Fig. 2: Glioblastoma
Figure/Graphic 2: Glioblastoma
Possible genetic pathways in glioblastomas. Glioblastomas can be differentiated into primary GBM (de novo occurrence) or secondary GBM, which originate from either a low-grade diffuse astrocytoma (WHO grade II) directly or via malignant transformation from an anaplastic astrocytoma WHO grade III. It has been demonstrated that both GBM pathways show genetic alterations at different time points and/ or in a different frequency. Some of them are shown in this figure which was modified from the literature [46].
 
Glioblastoma
Previous Image Next Image  


Figure/Graphic 2: Glioblastoma
Possible genetic pathways in glioblastomas. Glioblastomas can be differentiated into primary GBM (de novo occurrence) or secondary GBM, which originate from either a low-grade diffuse astrocytoma (WHO grade II) directly or via malignant transformation from an anaplastic astrocytoma WHO grade III. It has been demonstrated that both GBM pathways show genetic alterations at different time points and/ or in a different frequency. Some of them are shown in this figure which was modified from the literature [46].
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum